Literature DB >> 31941375

Long-term Effects of Skin Tearing on Outcomes After Collagenase Treatment of Dupuytren Contractures.

Dafang Zhang1,2, Philip Blazar1,2, Kyra A Benavent1, Brandon E Earp1,2.   

Abstract

Background: The objective of this study was to compare the rates of recurrence, additional treatment, patient satisfaction, and willingness to undergo Clostridium histolyticum (CCH) treatment again for Dupuytren disease in patients with and without skin tearing at minimum 5-year follow-up.
Methods: We identified 199 digits in 142 patients who underwent CCH treatments for Dupuytren disease from April 2010 to December 2013 with minimum 5-year follow-up. Patients were contacted by telephone to collect our response variables: perceived recurrence of contracture, additional treatment, satisfaction, and willingness to undergo CCH treatment again. Medical records were reviewed for skin tearing at manipulation and patient-related and disease-specific variables.
Results: At the time of manipulation, 16 out of 142 patients (11%) and 22 out of 199 digits (11%) had skin tearing. Older age was associated with skin tearing. At an average 7.2-year follow-up, the mean satisfaction was 7.1 ± 2.6 on a 1 to 10 Likert scale for patients with skin tearing and 6.5 ± 3.4 for patients without skin tearing. Eighty-one percent of patients with skin tearing expressed willingness to undergo CCH treatment again, compared with 68% of patients without skin tearing. Perceived recurrence of contracture occurred in 82% of digits with skin tearing and 80% of digits without skin tearing. Additional treatment was performed in 45% of digits with skin tearing and 54% of digits without skin tearing. No difference was statistically significant. Conclusions: Although skin tearing at CCH manipulation complicates the short-term course following CCH treatment, it does not affect long-term perceived contracture recurrence or patient satisfaction.

Entities:  

Keywords:  Dupuytren contracture; Dupuytren disease; Xiaflex; collagenase; collagenase Clostridium histolyticum; patient satisfaction; recurrence; skin tear; skin tearing

Mesh:

Substances:

Year:  2020        PMID: 31941375      PMCID: PMC8647323          DOI: 10.1177/1558944719898836

Source DB:  PubMed          Journal:  Hand (N Y)        ISSN: 1558-9447


  13 in total

1.  Cost-effectiveness of open partial fasciectomy, needle aponeurotomy, and collagenase injection for dupuytren contracture.

Authors:  Neal C Chen; Melissa J Shauver; Kevin C Chung
Journal:  J Hand Surg Am       Date:  2011-10-05       Impact factor: 2.230

Review 2.  Trends in the Treatment of Dupuytren Disease in the United States Between 2007 and 2014.

Authors:  Marc D Lipman; Samuel Evan Carstensen; Dylan Nicole Deal
Journal:  Hand (N Y)       Date:  2016-05-03

3.  Risk Factors for Skin Tearing in Collagenase Treatment of Dupuytren Contractures.

Authors:  Dafang Zhang; Brandon E Earp; Philip Blazar
Journal:  J Hand Surg Am       Date:  2019-08-14       Impact factor: 2.230

4.  Collagenase Clostridium Histolyticum versus Limited Fasciectomy for Dupuytren's Contracture: Outcomes from a Multicenter Propensity Score Matched Study.

Authors:  Chao Zhou; Steven E R Hovius; Harm P Slijper; Reinier Feitz; Christianne A Van Nieuwenhoven; Adriana J Pieters; Ruud W Selles
Journal:  Plast Reconstr Surg       Date:  2015-07       Impact factor: 4.730

5.  Comparison of Treatment Outcome After Collagenase and Needle Fasciotomy for Dupuytren Contracture: A Randomized, Single-Blinded, Clinical Trial With a 1-Year Follow-Up.

Authors:  Joakim Strömberg; Allan Ibsen-Sörensen; Jan Fridén
Journal:  J Hand Surg Am       Date:  2016-07-27       Impact factor: 2.230

6.  Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease.

Authors:  David Gilpin; Stephen Coleman; Stephen Hall; Anthony Houston; Jeff Karrasch; Nigel Jones
Journal:  J Hand Surg Am       Date:  2010-12       Impact factor: 2.230

7.  Dupuytren Contracture Recurrence Following Treatment With Collagenase Clostridium histolyticum (CORDLESS [Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study]): 5-Year Data.

Authors:  Clayton A Peimer; Philip Blazar; Stephen Coleman; F Thomas D Kaplan; Ted Smith; Tommy Lindau
Journal:  J Hand Surg Am       Date:  2015-06-18       Impact factor: 2.230

8.  Outcome of Dupuytren Contractures After Collagenase Clostridium Histolyticum Injection: A Single-institution Experience.

Authors:  Yin Kan Hwee; Daniel Park; Marisa Vinas; Christopher Litts; David Friedman
Journal:  Ann Plast Surg       Date:  2017-08       Impact factor: 1.539

9.  Efficacy and safety of collagenase clostridium histolyticum injection for Dupuytren contracture: short-term results from 2 open-label studies.

Authors:  Jörg Witthaut; Graeme Jones; Nebojsa Skrepnik; Harvey Kushner; Anthony Houston; Tommy R Lindau
Journal:  J Hand Surg Am       Date:  2012-12-04       Impact factor: 2.230

10.  Injectable collagenase clostridium histolyticum for Dupuytren's contracture.

Authors:  Lawrence C Hurst; Marie A Badalamente; Vincent R Hentz; Robert N Hotchkiss; F Thomas D Kaplan; Roy A Meals; Theodore M Smith; John Rodzvilla
Journal:  N Engl J Med       Date:  2009-09-03       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.